A 2-COHORT, MULTI-CENTRE, RANDOMIZED, DOUBLE BLIND (3RD PARTY OPEN), PLACEBO CONTROLLED 4-WAY CROSSOVER STUDY TO ASSESS THE EFFICACY OF SINGLE ORAL DOSES OF PF-00446687 ON ERECTILE FUNCTION IN MEN SUFFERING FROM ERECTILE DYSFUNCTION, USING 100 MG SILDENAFIL AS A POSITIVE CONTROL To confirm the efficacy of single oral doses of PF-00446687 200 mg in improving penile erectile activity, utilizing the penile plethysmography (Rigiscan® Plus) technique, in males suffering from erect...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION WHO HAVE COMPLETED STUDY B1321001 The primary objective of this study is to evaluate the efficacy of sitaxsentan (100 mg once daily) plus sildenafil (20 mg TID) as compared to sitaxsentan monotherapy by determining time to clinical wo...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 6 MONTH, PROSPECTIVE, OPEN-LABEL MULTIPLE CENTER EXTENSION TRIAL TO EVALUATE THE LONG TERM SAFETY AND SUSTAINED EFFICACY OF FRAGMIN IN THE TREATMENT OF CHRONIC FOOT ULCERS IN DIABETIC PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE The primary objective of this 6 month open-label extension trial is to evaluate long-term safety and tolerability of dalteparin in treatment of chronic neuroischaemic foot ulcers in diabetic patients ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Oral Revatio in Pediatric PAH - Long-term follow-on Study to A1481131 The primary objective is to assess the safety and tolerability of oral sildenafil in the chronic treatment of pediatric subjects with PAH.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE 2B, PARALLEL, DOUBLE BLIND, DOUBLE DUMMY, ACTIVE COMPARATOR AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND EFFICACY OF 6-WEEK QD ADMINISTRATION OF PF-00610355 CRC-749 DPI IN PATIENTS WITH MODERATE COPD To test all doses (100, 300 and 600 µg QD) of PF-00610355 and salmeterol 50 µg (BID) for superior efficacy on trough FEV1 vs placebo at Week 6.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

PHASE 2A MULTI-CENTRE, DOUBLE BLIND (3RD PARTY OPEN), PLACEBO CONTROLLED 3-WAY CROSS-OVER STUDY TO INVESTIGATE THE EFFECT OF SINGLE DOSES OF PF-00446687 ON SEXUAL AROUSAL AND SEXUAL DESIRE IN WOMEN SUFFERING FROM FEMALE SEXUAL DYSFUNCTION (FSD) • To assess the effect of single doses of PF-00446687 on acute sexual arousal and sexual interest as assessed by questionnaires in post-menopausal women suffering from FSD. • To assess the effect of s...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 24-WEEK, MULTICENTRE TRIAL, COMPRISING A 12-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE FOLLOWED BY A 12-WEEK OPEN-LABEL PHASE, TO EVALUATE THE EFFICACY AND SAFETY OF A FESOTERODINE FLEXIBLE DOSE REGIMEN IN ELDERLY PATIENTS WITH OVERACTIVE BLADDER To compare the efficacy, in terms of a reduction of urgency episodes, of 12-weeks flexible dose Fesoterodine relative to placebo in elderly subjects with OAB.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune